---

Study the effect of Vitamin D3 in newly diagnosed acute myeloid leukemia

Full Text PDF

---

Original Article

Author Details : Shatha M. J. Al-Khateeb , Raghada Shams Akram, Mohammad Ali Kareem, Fatma Abdalhamza Obed*

Volume : 11, Issue : 1, Year : 2024

Article Page : 72-76

https://doi.org/10.18231/j.ijpca.2024.010

Suggest article by email

Get Permission

Abstract

Objective: This study is aimed to put light on the effect of vitamin D3 (VitD3) in newly diagnosed acute myeloid leukemia (AML) patients.
Materials and Methods: The AML patients consisted of sixty patients (30 male, 30 female). The average age of patients was (36.44±8.44) years (range 25-45). Thirty healthy subjects were considered as controls (15 male and 15 female), and the average age of control group was (32.22±5.13) years. All subjects had to go through clinical examination to determine existence of other diseases in addition to evaluate some tests as complete blood count [hemoglobin (Hb), platelet (PLT), and white blood cells (WBCs)], ferritin, FBS (fasting blood sugar), TG (triglycerides), TC (total cholesterol), and HDL (high density lipoprotein cholesterol) (HDL-Ch), urea, and creatinine. Vitamin D3 was measured by minividase Biomerux/French.
Results: The VitD3 was highly significantly lower in AML patients than in controls (p=0.001). While, VitD3 was lower in male than in female AML patients but the difference was not statistically significant. There were statistically significant positive correlations between VitD3 and Hb, PLT, Wbc, ferritin, FBS, and TG in both male and female AML patients.
Conclusion: These findings suggest that lower serum concentrations of vitamin D3 may possibly be considered as a potential factor for early assessment of acute myeloid leukemia.

Keywords: Acute myeloid leukemia, Vitamin D3, Ferritin, Male, Female

How to cite : Al-khateeb S M J, Akram R S, Kareem M A, Obed F A, Study the effect of Vitamin D3 in newly diagnosed acute myeloid leukemia. Int J Pharm Chem Anal 2024;11(1):72-76

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.